Rockefeller Capital Management L.P. Ligand Pharmaceuticals Inc Transaction History

Rockefeller Capital Management L.P.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 02, 2022	BUY	$0.01 - $107.56 $3 - $37,430	348 Added 155.36%	572 $49,000
Q1 2022 May 13, 2022	SELL	$94.99 - $151.56 $7,029 - $11,215	-74 Reduced 24.83%	224 $25,000
Q4 2021 Feb 14, 2022	BUY	$127.69 - $165.85 $12,513 - $16,253	98 Added 49.0%	298 $46,000
Q3 2021 Nov 12, 2021	SELL	$102.33 - $144.73 $7,265 - $10,275	-71 Reduced 26.2%	200 $27,000
Q4 2020 Feb 12, 2021	BUY	$80.55 - $106.05 $6,121 - $8,059	76 Added 38.97%	271 $26,000
Q3 2020 Nov 13, 2020	BUY	$89.56 - $126.72 $9,045 - $12,798	101 Added 107.45%	195 $17,000
Q2 2020 Aug 12, 2020	SELL	$68.28 - $123.65 $2,253 - $4,080	-33 Reduced 25.98%	94 $11,000
Q1 2020 May 12, 2020	BUY	$63.37 - $107.88 $7,414 - $12,621	117 Added 1170.0%	127 $9,000
Q4 2019 Feb 07, 2020	BUY	$96.94 - $113.59 $969 - $1,135	10 New	10 $1,000
Q2 2019 Aug 09, 2019	SELL	$107.38 - $129.34 $22,871 - $27,549	-213 Closed	0 $0
Q1 2019 May 10, 2019	BUY	$105.93 - $142.47 $16,842 - $22,652	159 Added 294.44%	213 $27,000
Q2 2018 Jul 31, 2018	BUY	$150.77 - $207.98 $8,141 - $11,230	54 New	54 $11,000

262

18M

26.8K

9.3K

Ticker LGND
Exchange OTC
Sector Healthcare
Industry Biotechnology
Shares Outstandng 16,882,800
Market Cap $1.94B
Description
Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19;...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.